SCHEMBL302802

SCHEMBL302802

CCN([C]=O)C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 8/20 0.47
ADH1C P00326 5/20 0.47
ADH1B P00325 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
PHGDH O43175 1/20 0.31
S1PR1 P21453 2/20 0.31
S1PR3 Q99500 2/20 0.31
TSHR P16473 1/20 0.31
XBP1 P17861 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9660578 1.00 ADH1A (0.47) ADH1AADH1CADH1BL3MBTL1MEN1
SCHEMBL9660966 1.00 ADH1A (0.47) ADH1AADH1CADH1BL3MBTL1MEN1
SCHEMBL967214 0.98 ADH1A (0.43) ADH1AADH1CADH1BL3MBTL1MEN1
SCHEMBL969251 0.95
SCHEMBL967293 0.88
SCHEMBL304405 0.83 ADH1A (0.50) ADH1AADH1CADH1B
SCHEMBL9660549 0.83 ADH1A (0.50) ADH1AADH1CADH1B
SCHEMBL9660999 0.83 ADH1A (0.50) ADH1AADH1CADH1B
SCHEMBL3024929 0.80 ADH1A (0.48) ADH1AADH1C
SCHEMBL9658873 0.79 ADH1A (0.43) ADH1AADH1CL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1416933-B8 SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR AMGEN INC (US) 2008-08-27 EP claimed
EP-1416933-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR Amgem, Inc. (US) 2004-05-12 EP claimed
CN-1402613-A Method for increasing yield of crops BAYER AGROCHEM KK (JP) 2003-03-12 CN claimed
WO-2003009847-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR AMGEM, INC. (US) 2003-02-06 WO claimed
WO-2001039595-A2 METHOD FOR INCREASING THE YIELD OF CROPS NIHON BAYER AGROCHEM K.K. (DE) 2001-06-07 WO claimed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP claimed
WO-1999021860-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 1999-08-05 WO claimed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US claimed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO claimed
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2020-04-30 US disclosed
EP-3438091-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-02-06 EP disclosed
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS AJINOMOTO CO., INC. (JP) 2019-01-24 US disclosed
EP-2318355-B1 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE BOEHRINGER INGELHEIM INT (DE) 2018-09-12 EP disclosed
US-9255070-B2 Method of deuteration using mixed catalyst WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2016-02-09 US disclosed
US-4091220-A RESPIRATORY TRACK FLUID SECRETION STIMULATORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) 1978-05-23 US disclosed
US-4055714-A POLYMERIZATION CATALYSTS PENNWALT CORPORATION (US) 1977-10-25 US disclosed
US-4045427-A POLYMERIZATION CATALYSTS PENNWALT CORPORATION (US) 1977-08-30 US disclosed
US-4045426-A POLYMERIZATION CATALYSTS PENNWALT CORPORATION (US) 1977-08-30 US disclosed
US-4042773-A REACTION WITH POLYMERS PENNWALT CORPORATION (US) 1977-08-16 US disclosed
US-3956269-A POLYMERIZATION CATALYSTS PENNWALT CORPORATION (US) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129458-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR ADH1A 1538/4885ADH1C 987/4885ADH1B 2438/4885
US-20190022039-A1 COMPOUND HAVING ENHANCING ACTIVITY FOR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR ACTIONS GLP1R, GPR119, GIPR ADH1A 1538/4885ADH1C 987/4885ADH1B 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.